{"filing":{"accession_number":"0001193125-26-252544","cik":"0000899460","ticker":"MNKD","company_name":"MANNKIND CORP","form":"8-K","filing_date":"2026-06-02","report_date":null,"primary_document":"mnkd-20260529.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/899460/000119312526252544/mnkd-20260529.htm"},"events":[{"id":7437,"run_id":6536,"accession_number":"0001193125-26-252544","anchor_item_number":"8.01","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"summary":"MannKind announced FDA approval of Afrezza for pediatric use (ages 6+) on May 29, 2026, and completion of the last remaining postmarketing requirement from the original 2014 approval. This regulatory milestone expands the addressable market to over 350,000 children and adolescents with diabetes in the U.S. and removes a material regulatory constraint. While this is a positive development, it does not fit neatly into the more specific event categories (not an earnings release, M\u0026A, impairment, or litigation); it is best classified as a material regulatory/product approval event.","company_name":"MANNKIND CORP","ticker":"MNKD","filing_date":"2026-06-02","form":"8-K","submitted_at":null,"items":[{"id":3538,"accession_number":"0001193125-26-252544","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"MannKind announced FDA approval of Afrezza for pediatric use (ages 6+) on May 29, 2026, and completion of the last remaining postmarketing requirement from the original 2014 approval. This regulatory milestone expands the addressable market to over 350,000 children and adolescents with diabetes in the U.S. and removes a material regulatory constraint. While this is a positive development, it does not fit neatly into the more specific event categories (not an earnings release, M\u0026A, impairment, or litigation); it is best classified as a material regulatory/product approval event.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-03T02:14:44.872698+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":3538,"accession_number":"0001193125-26-252544","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"MannKind announced FDA approval of Afrezza for pediatric use (ages 6+) on May 29, 2026, and completion of the last remaining postmarketing requirement from the original 2014 approval. This regulatory milestone expands the addressable market to over 350,000 children and adolescents with diabetes in the U.S. and removes a material regulatory constraint. While this is a positive development, it does not fit neatly into the more specific event categories (not an earnings release, M\u0026A, impairment, or litigation); it is best classified as a material regulatory/product approval event.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-03T02:14:44.872698+00:00","company_name":"MANNKIND CORP","ticker":"MNKD","filing_date":"2026-06-02"}]}